Biosimilars maker Samsung Bioepis, part of South Korea's top family-run conglomerate Samsung Group [SAGR.UL], said on Monday it is seeking regulatory approval in Europe to sell its copy of AbbVie Inc's rheumatoid arthritis drug Humira. Samsung Bioepis said in a statement the European Medicines Agency has accepted for review its application to sell its biosimilar of Humira, the world's best-selling drug that generated $14 billion in sales last year.
View original here:
Samsung Bioepis seeks Europe approval for its Humira copy
